Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection

NCT05921162 is registered in ClinicalTrials.gov with Nanoscope Therapeutics Inc. as lead sponsor.

NCT NCT05921162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05921162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection
Lead sponsor
Nanoscope Therapeutics Inc.
Phase
Observational
Overall status
Enrolling by invitation
Start date
July 14, 2023
Completion date
May 31, 2025
Enrollment
11 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal degeneration, retinal disease, retinitis pigmentosa